-
Decipher Labs Raises $14 Million in Series A Funding to Advance AI-Powered Drug Discovery Platform
Decipher Labs, a leading provider of AI-powered drug discovery solutions, today announced it has raised $14 million in Series A funding. The funding round was led by ARCH Venture Partners and included participation from existing investors, including Brio Ventures, Gilead Sciences, Illumina Ventures, and Pacific 8 Ventures.
-
Decipher Labs and Pacific 8 Ventures Launch New AI Initiative to Advance Precision Medicine
Decipher Labs, a leading provider of AI-powered drug discovery solutions, and Pacific 8 Ventures, a venture capital firm focused on healthcare and technology, today announced the launch of a new AI initiative to advance precision medicine. The initiative will bring together Decipher's AI platform with Pacific 8's expertise in healthcare and technology to develop new AI-powered solutions for precision medicine.
-
Decipher Labs Partners with Google Cloud to Accelerate Drug Discovery
Decipher Labs, a leading provider of AI-powered drug discovery solutions, today announced a partnership with Google Cloud to accelerate drug discovery. The partnership will combine Decipher's AI platform with Google Cloud's powerful computing and data analytics capabilities to develop new AI-powered solutions for drug discovery.
-
Decipher Labs Announces Collaboration with Bio-Rad to Provide Automated Sample Preparation for Next-Generation Sequencing Workflows
Collaboration combines Decipher Labs' single-cell sample preparation technology with Bio-Rad's automated nucleic acid purification systems.
-
Decipher Labs Introduces New High-Throughput scRNA-seq Panels for Unbiased Single-Cell Gene Expression Profiling
New panels provide comprehensive coverage of the human transcriptome and enable researchers to study a wider range of cell types and biological processes at higher throughput.
-
Decipher Labs Receives ISO 13485:2016 Certification for its Single-Cell Sample Preparation System
Certification recognizes Decipher Labs' commitment to quality and compliance in the design, development, and manufacture of its medical devices.
-
Decipher Labs Raises $50 Million in Series C Funding to Accelerate Global Expansion and Product Innovation
Decipher Labs, a leading molecular diagnostics company, today announced the closing of a $50 million Series C funding round. The round was led by new investor ARCH Venture Partners, with participation from existing investors Redmile Group, Sofinnova Partners, and B Capital Group.
-
Decipher Labs Announces Collaboration with Intermountain Healthcare to Develop and Commercialize New Molecular Diagnostic Tests
Decipher Labs, a leading molecular diagnostics company, today announced a collaboration with Intermountain Healthcare, a nationally recognized health system, to develop and commercialize new molecular diagnostic tests.
-
Decipher Labs Appoints David Erickson as Chief Operating Officer
Decipher Labs, a leading molecular diagnostics company, today announced the appointment of David Erickson as Chief Operating Officer, effective immediately.
-
Decipher Labs Announces New Partnership with Roche Diagnostics
The partnership will focus on the development and commercialization of Decipher Labs' proprietary artificial intelligence (AI)-powered genomic testing platform, which enables personalized treatment recommendations for cancer patients.
-
Decipher Labs Raises $100 Million in Series D Funding
The funding round was led by new investor SoftBank Vision Fund 2, with participation from existing investors including GV, Khosla Ventures, and Polaris Partners.
-
Decipher Labs Launches New AI-Powered Cancer Test
The test, called Decipher GRID, is designed to help doctors make more informed decisions about the care of their cancer patients.
